Orion Oyj ADR (ORINY)

Currency in USD
41.50
0.00(0.00%)
Closed·
ORINY Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
ORINY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
41.5041.50
52 wk Range
21.7041.60
Key Statistics
Prev. Close
41.5
Open
41.5
Day's Range
41.5-41.5
52 wk Range
21.7-41.6
Volume
525
Average Volume (3m)
283
1-Year Change
96.68%
Book Value / Share
7.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORINY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Orion Oyj ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Orion Oyj ADR Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies. It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Employees
3700

Compare ORINY to Peers and Sector

Metrics to compare
ORINY
Peers
Sector
Relationship
P/E Ratio
26.2x17.6x−0.5x
PEG Ratio
0.420.620.00
Price/Book
10.8x2.4x2.6x
Price / LTM Sales
5.9x2.2x3.2x
Upside (Analyst Target)
-11.7%41.4%
Fair Value Upside
Unlock19.8%6.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.69%
Dividend Yield
1.12%
Industry Median 2.81%
Annualised payout
0.46
Paid unevenly
5-Years Growth
+1.80%
Growth Streak

Earnings

Latest Release
Jul 18, 2025
EPS / Forecast
0.59 / --
Revenue / Forecast
416.50M / --
EPS Revisions
Last 90 days

ORINY Income Statement

FAQ

What Stock Exchange Does Orion ADR Trade On?

Orion ADR is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Orion ADR?

The stock symbol for Orion ADR is "ORINY."

What Is the Orion ADR Market Cap?

As of today, Orion ADR market cap is 11.64B.

What Is Orion ADR's Earnings Per Share (TTM)?

The Orion ADR EPS (TTM) is 2.69.

From a Technical Analysis Perspective, Is ORINY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Orion ADR Stock Split?

Orion ADR has split 0 times.

How Many Employees Does Orion ADR Have?

Orion ADR has 3700 employees.

What is the current trading status of Orion ADR (ORINY)?

As of 27 Jul 2025, Orion ADR (ORINY) is trading at a price of 41.50, with a previous close of 41.50. The stock has fluctuated within a day range of 41.50 to 41.50, while its 52-week range spans from 21.70 to 41.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.